No Clear Winner in BMS, Exelixis/Ipsen First-line Renal Cancer Race

 
• By Kevin Grogan
  
Wrestlers
B-MS and Exelixis/Ipsen's renal cancer drugs are battling to be first-line therapy • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer